Bubs Australia (ASX:BUB) disclosed full-year revenue of $111.9 million for the year ended 30 June 2026, representing a 9.2% increase, alongside a reported net loss after tax of $4.6 million and a reported EBITDA loss of $1.8 million, as Chair Paul Jensen and CEO Joe Coote addressed shareholders at the company's 2026 Annual General Meeting in Melbourne on 18 November 2026.
Key Points
- Revenue of $111.9 million for FY26, up 9.2%, with United States revenue growing 24% to $65.8 million
- Reported EBITDA loss of $1.8 million and net loss after tax of $4.6 million; gross margin declined to 39.8%
- Underlying EBITDA of $5.3 million for FY26, described as a significant improvement on the prior year
- US tariff costs increased from approximately $0.3 million in the first half to $2.3 million in the second half of FY26
- Pascal De Petrini and Lori Tauber Marcus joined the Board during FY26 and attended their first Bubs AGM
FY26 Financial Results for the Year Ended 30 June 2026
Bubs Australia delivered revenue of $111.9 million for the year ended 30 June 2026, a 9.2% increase on the prior period. The company recorded a reported EBITDA loss of $1.8 million and a net loss after tax of $4.6 million. Gross margin declined to 39.8%. The filing attributed these outcomes to airfreight expenditure, additional United States tariff costs and costs associated with an industry regulatory reset. On an underlying basis, the company reported EBITDA of $5.3 million for FY26, with the difference between underlying and reported results reflecting those specific cost items incurred during the year.
Airfreight, US Tariffs and Regulatory Reset Costs
During FY26, the company incurred approximately $3.0 million in airfreight expenditure to support product availability in the United States. United States tariff costs increased from approximately $0.3 million in the first half of the year to $2.3 million in the second half. The cost of the regulatory reset for Bubs was disclosed as $3.9 million. The filing states that the company invested substantially in rebuilding inventory during FY26 and noted that the task is to convert that investment into sales and cash while continuing to improve forecasting, stock allocation and supply-chain efficiency.
Permanent FDA Authorisation and Board Changes
The Chair's address disclosed that Bubs secured permanent FDA authorisation for its three infant formula products during the period, described in the filing as establishing a long-term platform in the company's largest market. Board members Pascal De Petrini and Lori Tauber Marcus joined during FY26 and attended their first Bubs AGM. The Chair noted the company's share price was approximately 8 cents at the time of the address and acknowledged shareholder concerns about share-price performance, financial position, governance, remuneration and accountability as matters the Board takes seriously.





Please wait processing your request...